CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts)

MLA

K. Harrow, et al. “CNS Activity of Ensartinib in ALK+ Non-Small Cell Lung Cancer (NSCLC) Patients (Pts).” Annals of Oncology, vol. 28, Apr. 2017, pp. ii31-ii32. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........025b119bff03bf9ac84bd3b304a59701&authtype=sso&custid=ns315887.

APA

K. Harrow, Sandip Pravin Patel, Joel W. Neal, Barbara J. Gitlitz, Karen L. Reckamp, Saiama N. Waqar, George R. Blumenschein, Leora Horn, Heather A. Wakelee, & F. Tan. (2017). CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology, 28, ii31-ii32.

Chicago

K. Harrow, Sandip Pravin Patel, Joel W. Neal, Barbara J. Gitlitz, Karen L. Reckamp, Saiama N. Waqar, George R. Blumenschein, Leora Horn, Heather A. Wakelee, and F. Tan. 2017. “CNS Activity of Ensartinib in ALK+ Non-Small Cell Lung Cancer (NSCLC) Patients (Pts).” Annals of Oncology 28 (April): ii31-ii32. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........025b119bff03bf9ac84bd3b304a59701&authtype=sso&custid=ns315887.